NCT00241462终止不适用
Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- AstraZeneca
- 入组人数
- 150
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal
- •Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status
- •Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment
排除标准
- •Life threatening metastases
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in FranceBreast CancerNCT00681369AstraZeneca217
已完成
不适用
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)Malignant Neoplasm of Breast Stage IVNCT01509625Isabel Blancas272
已完成
不适用
Faslodex Specific Clinical Experience InvestigationBreast CancerNCT01501266AstraZeneca660
已完成
不适用
Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast CancerBreast CancerNCT00878930AstraZeneca500
已完成
2 期
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast CancerMetastatic Breast CancerNCT00274469AstraZeneca205